Medivation (MDVN) : Traders are bullish on Medivation (MDVN) as it has outperformed the S&P 500 by a wide margin of 5.6% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.32%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.38% in the last 1 week, and is up 6.69% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.6% and the 50-Day Moving Average is 7.6%. Medivation (NASDAQ:MDVN): stock turned positive on Friday. Though the stock opened at $65.54, the bulls momentum made the stock top out at $66.19 level for the day. The stock recorded a low of $65.22 and closed the trading day at $66.02, in the green by 0.64%. The total traded volume for the day was 1,568,717. The stock had closed at $65.6 in the previous days trading.
The company Insiders own 3.54% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.29% . Institutional Investors own 87.68% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of -1.69%. Also, JMP Securities downgrades their rating on the shares of Medivation (NASDAQ:MDVN). The current rating of the shares is Market Perform. Earlier, the shares were rated a Market Outperform by the brokerage firm. The rating by the firm was issued on August 10, 2016.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.